Want to see HK:3681 full AI Analyst Report?
3681 Stock Chart & Stats
HK$1.10
HK$0.02(1.67%)
At close: 4:00 PM EDT
HK$1.10
HK$0.02(1.67%)
Day’s Range― - ―
52-Week RangeHK$0.99 - HK$2.74
Previous CloseN/A
Volume690.90K
Average Volume (3M)6.26M
Market Cap
HK$1.50B
Enterprise ValueHK$1.79K
Total Cash (Recent Filing)HK$382.40M
Total Debt (Recent Filing)HK$338.64M
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding1,386,638,300
10 Day Avg. Volume8,278,616
30 Day Avg. Volume6,255,789
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)2.91
Price to Sales (P/S)0.00
P/FCF Ratio-15.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.21
Revenue Forecast (FY)HK$8.71M
Bulls Say, Bears Say
Bulls Say
Improved Balance-Sheet LeverageLower leverage improves financial flexibility and may reduce refinancing pressure compared with 2024. This provides a stronger base for continued development, although persistent losses mean the balance sheet remains dependent on disciplined funding.
Narrower Net LossesA narrower loss indicates some progress in controlling the company’s cost structure or reducing development-related pressure. If sustained, this could extend the funding runway and improve the path toward eventual profitability.
Reduced Free-Cash-Flow BurnSlower cash consumption can preserve resources for antibody research and clinical programs for longer. The improvement is constructive for funding durability, though cash generation remains negative and does not yet remove financing dependence.
Bears Say
Revenue Collapsed To ZeroZero annual revenue signals that commercialization has not yet achieved meaningful scale. Without product sales or dependable partnering income, the company has limited internal funding capacity for ongoing antibody development and regulatory activities.
Structurally Negative Cash FlowRecurring operating and free-cash-flow deficits require external financing to sustain research and development. This creates ongoing dilution or liquidity risk and may constrain the company if funding conditions tighten before products generate revenue.
Persistent Loss-Making Development ModelContinued losses reflect the long, capital-intensive path from antibody discovery through clinical development and approval. Until a candidate is commercialized or partnered on material terms, profitability and self-sustaining operations remain uncertain.
SinoMab Bioscience Ltd. News
3681 FAQ
What was SinoMab Bioscience Ltd.’s price range in the past 12 months?
SinoMab Bioscience Ltd. lowest stock price was HK$0.99 and its highest was HK$2.74 in the past 12 months.
What is SinoMab Bioscience Ltd.’s market cap?
SinoMab Bioscience Ltd.’s market cap is HK$1.50B.
When is SinoMab Bioscience Ltd.’s upcoming earnings report date?
SinoMab Bioscience Ltd.’s upcoming earnings report date is Aug 31, 2026 which is tomorrow.
How were SinoMab Bioscience Ltd.’s earnings last quarter?
SinoMab Bioscience Ltd. released its earnings results on Mar 23, 2026. The company reported -HK$0.044 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is SinoMab Bioscience Ltd. overvalued?
According to Wall Street analysts SinoMab Bioscience Ltd.’s price is currently Overvalued.
Does SinoMab Bioscience Ltd. pay dividends?
SinoMab Bioscience Ltd. does not currently pay dividends.
What is SinoMab Bioscience Ltd.’s EPS estimate?
SinoMab Bioscience Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SinoMab Bioscience Ltd. have?
SinoMab Bioscience Ltd. has 1,386,638,300 shares outstanding.
What happened to SinoMab Bioscience Ltd.’s price movement after its last earnings report?
SinoMab Bioscience Ltd. reported an EPS of -HK$0.044 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.183%.
Which hedge fund is a major shareholder of SinoMab Bioscience Ltd.?
Currently, no hedge funds are holding shares in HK:3681
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SinoMab Bioscience Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
44.64%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
26.20%
Trailing 12-Months
Company Description
SinoMab Bioscience Ltd.
SinoMab BioScience Limited is a biopharmaceutical enterprise that specializes in the comprehensive process of discovering, developing, producing, and marketing therapeutic solutions for various immunological disorders. Their approach predominantly involves monoclonal antibody (mAb)-based biologics. A key asset in their portfolio is SM03, an innovative anti-CD22 monoclonal antibody. This drug is currently in Phase III clinical trials for rheumatoid arthritis (RA), with additional clinical investigations underway for other immune-related conditions such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company is also progressing with SN1011, a Bruton's tyrosine kinase inhibitor. This compound is in Phase II clinical trials for pemphigus and has commenced Phase I trials for multiple sclerosis, SLE, and neuromyelitis optica spectrum disorder (NMOSD). Furthermore, SinoMab maintains an active preclinical pipeline. This includes SM17, which targets asthma, atopic dermatitis, and idiopathic pulmonary fibrosis; SM06, intended for RA, SLE, NMOSD, and SS; SM09, in development for NHL and RA; and TNF2, focused on a range of autoimmune diseases. Founded in 2001, SinoMab BioScience Limited is based in Pak Shek Kok, Hong Kong, and conducts its business activities across Mainland China, the Cayman Islands, and Hong Kong.
Technical Analysis
Genor Biopharma Holdings Limited
―
Alphamab Oncology
―
Mabpharm Limited
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―